Sagimet Biosciences Files 8-K, Confirms Nasdaq Listing

Ticker: SGMT · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1400118

Complexity: simple

Sentiment: neutral

Topics: administrative, compliance, corporate-governance

TL;DR

**Sagimet Biosciences filed a routine 8-K, no major news, just administrative updates.**

AI Summary

Sagimet Biosciences Inc. filed an 8-K on January 30, 2024, reporting an event that occurred on January 25, 2024. This filing primarily serves to update administrative information, such as confirming its registration on The Nasdaq Global Market under the symbol SGMT for its Series A Common Stock. For investors, this filing is a routine administrative update and does not contain new financial or operational news that would significantly impact the stock's valuation, but it confirms the company's continued compliance with SEC reporting requirements.

Why It Matters

This filing is a standard administrative update, confirming Sagimet Biosciences' continued compliance with SEC regulations and its listing on The Nasdaq Global Market. It provides no new material financial or operational information.

Risk Assessment

Risk Level: low — This filing is purely administrative and does not introduce any new financial or operational risks to the company.

Analyst Insight

A smart investor would recognize this as a routine administrative filing with no immediate impact on the company's fundamentals or stock price. No specific action is warranted based solely on this filing.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Sagimet Biosciences Inc.?

This 8-K filing by Sagimet Biosciences Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily serving to report 'Other Events' and 'Financial Statements and Exhibits' as of January 25, 2024, and to confirm administrative details like its Nasdaq listing.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 25, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.

What is the trade symbol and exchange for Sagimet Biosciences Inc.'s stock?

Sagimet Biosciences Inc.'s Series A Common Stock, with a $0.0001 par value per share, trades under the symbol SGMT on The Nasdaq Global Market, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' table.

What is the business address of Sagimet Biosciences Inc.?

The business address for Sagimet Biosciences Inc. is 155 Bovet Road, Suite 303, San Mateo, California 94402, according to the 'BUSINESS ADDRESS' section of the filing.

Is this 8-K filing intended to satisfy any other filing obligations?

Yes, the filing indicates that it is intended to simultaneously satisfy the filing obligation of the registrant under Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425), Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12), Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)), and Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-30 16:05:22

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 30, 2024, Sagimet Biosciences Inc. (the " Company ") closed an underwritten public offering (the " Offering ") of 9,000,000 shares of the Company's Series A common stock, par value $0.0001 per share (the " Common Stock ") at the public offering price of $12.50 per share. All of the shares in the Offering were sold by the Company, resulting in approximately $112.5 million of gross proceeds, before deducting the underwriters' discounts and commissions and other estimated offering expenses payable by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,350,000 additional shares of Common Stock in the Offering. Goldman Sachs & Co. LLC, TD Cowen and Leerink Partners acted as joint book-running managers for the offering. JMP Securities, A Citizens Company, acted as the lead manager for the offering. The Company currently intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and short-term investments, (i) to advance the development of denifanstat and begin startup activities related to the pivotal Phase 3 program in non-alcoholic steatohepatitis, including manufacturing of additional drug supply, (ii) to advance the development of TVB-3567 and submit an investigational new drug application for a Phase 1 clinical trial for the treatment of acne and (iii) for other general corporate purposes, including additional clinical development, working capital and operating expenses. The Offering was made pursuant to the Company's effective registration on January 23, 2024 and declared effective by the SEC on January 25, 2024, and a final prospectus filed with the SEC on June 29, 2024. On January 25, 2024, the Company issued a press release announcing the pricing of the Offering, a copy of which is filed as Exhibit 99.1 to

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Sagimet Biosciences Inc., dated January 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: January 30, 2024 By: /s/ David Happel David Happel Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing